Antimicrobial Resistance in ESKAPE Pathogens

David M P De Oliveira; Brian M Forde; Timothy J Kidd; Patrick N A Harris; Mark A Schembri; Scott A Beatson; David L Paterson; Mark J Walker

doi:10.1128/CMR.00181-19

Antimicrobial Resistance in ESKAPE Pathogens

Clin Microbiol Rev. 2020 May 13;33(3):e00181-19. doi: 10.1128/CMR.00181-19. Print 2020 Jun 17.

Authors

David M P De Oliveira^{1

2}, Brian M Forde^{1

2}, Timothy J Kidd^{1

2}, Patrick N A Harris^{2

3}, Mark A Schembri^{1

2}, Scott A Beatson^{1

2}, David L Paterson^{2

3}, Mark J Walker^{4

2}

Affiliations

¹ School of Chemistry and Molecular Biosciences, The University of Queensland, QLD, Australia.
² Australian Infectious Diseases Research Centre, The University of Queensland, QLD, Australia.
³ UQ Centre for Clinical Research, The University of Queensland, QLD, Australia.
⁴ School of Chemistry and Molecular Biosciences, The University of Queensland, QLD, Australia mark.walker@uq.edu.au.

Abstract

Antimicrobial-resistant ESKAPE ( Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens represent a global threat to human health. The acquisition of antimicrobial resistance genes by ESKAPE pathogens has reduced the treatment options for serious infections, increased the burden of disease, and increased death rates due to treatment failure and requires a coordinated global response for antimicrobial resistance surveillance. This looming health threat has restimulated interest in the development of new antimicrobial therapies, has demanded the need for better patient care, and has facilitated heightened governance over stewardship practices.

Keywords: Acinetobacter; Enterobacter; Enterobacterales; Enterococcus; Klebsiella; Pseudomonas aeruginosa; Staphylococcus aureus; antibiotic resistance; multidrug resistance.

Publication types

Review

MeSH terms

Anti-Bacterial Agents / pharmacology*
Bacteria / drug effects*
Bacteria / genetics*
Bacterial Infections / drug therapy*
Bacterial Infections / microbiology
Drug Discovery*
Drug Resistance, Multiple, Bacterial*
Humans

Substances

Anti-Bacterial Agents